Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4384 - Evaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Leukaemia

Presenters

Lisa Häcker

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

L. Häcker1, M. Tassara2, P. Brossart3, G. Held4, H.A. Horst5, M. Ringhoffer6, C. Köhne7, S. Kremers8, A. Raghavachar9, G. Wulf10, H. Kirchen11, D. Nachbaur12, M. Wattad13, A. Benner14, D. Weber1, V.I. Gaidzik1, P. Paschka1, K. Döhner1, H. Döhner1, R. Schlenk15

Author affiliations

  • 1 Internal Medicine, University Hospital Ulm, 89081 - ulm/DE
  • 2 Medical Oncology, San Raffaele Hospital, 20132 - Milan/IT
  • 3 Medical Oncology, University Hospital Bonn, 53127 - Bonn/DE
  • 4 Medical Oncology, University Hospital Saarland, 66424 - Homburg/DE
  • 5 Medical Oncology, University Hospital Kiel, 24105 - Kiel/DE
  • 6 Medical Oncology, Klinikum Karlsruhe, 76133 - Karlsruhe/DE
  • 7 Medical Oncology, Klinikum Oldenburg, 26133 - Oldenburg/DE
  • 8 Medical Oncology, Krankenhaus Lebach, 66882 - Lebach/DE
  • 9 Medical Oncology, Klinikum Wuppertal, 42283 - Wuppertal/DE
  • 10 Medical Oncology, Universitätsmedizin Göttingen, 37075 - Göttingen/DE
  • 11 Medical Oncology, Krankenhaus der Barmherzigen Brüder, 54292 - Trier/DE
  • 12 Medical Oncology, University Hospital Innsbruck, 6020 - Innsbruck/AT
  • 13 Medical Oncology, Klinikum Essen, 45239 - Essen/DE
  • 14 Division Of Biostatistics, German Cancer Research Center, 69120 - Heidelberg/DE
  • 15 Nct Trial Center, German Cancer Research Center, 69120 - Heidelberg/DE
More

Resources

Abstract 4384

Background

Progress in the treatment of acute myeloid leukemia (AML) in older patients (pts) is still limited. In the randomized part of the AMLSG 06-04 trial, valproic acid (VPA) was evaluated in combination with intensive therapy plus all-trans retinoic acid (ATRA) in older pts (>60 years) with newly diagnosed AML. The randomized part of the study (cohort-1) was terminated due to excessive VPA-induced toxicity (Tassara et al, Blood 2014;123:4027-36.). The study was amended thereafter (cohort-2) to evaluate a cytarabine dose-intensifcation in first consolidation therapy. Here we report on the comparison of the two cohorts.

Methods

Between 2004 and 2008, patients were treated in cohort-1 (n = 186) and cohort-2 (n = 376). 2 cycles of induction therapy (ATRA, idarubicin, cytarabine, n = 93 with VPA) were followed by consolidation-1 (mitoxantrone, ATRA, cytarabine [cohort-1, 0.5g/m2; cohort-2, 1g/m2] bid, days 1-3) and consoldation-2 (idarubicin, etoposide, ATRA).

Results

Median age was 68 (range, 60-84) years without difference between the cohorts (p = 0.49). Complete remission (CR) rates after induction therapy were 45% and 48% (p = 0.59) in cohort-1 and -2, respectively. There were no significant differences in the cumulative incidences of relapse (CIR, p = 0.26) and death (p = 0.51) between cohort-1 and -2 with CIR of 63% (SE, 4.8%) in cohort-1 compared to 51% (SE, 6.3%) in cohort-2. A Cox regression model on overall survival revealed older age (hazard ratio (HR) for a 10 years difference, 1.97, p 

Conclusions

Although evaluated in a cohort- rather than a randomized study, intensification of cytarabine dosage in consolidation therapy seems to improve survival.

Clinical trial identification

NCT00151255

Legal entity responsible for the study

University Hospital Ulm

Funding

University Ulm, Pfizer

Disclosure

R. Schlenk: Research funding: Novartis, Pfizer, Amgen, AstraZeneca, PharmaMar; Speakers bureau: Novartis, Pfizer; Advisory board: Daiichi Sankyo, Novartis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.